Covalon to Participate in the American Nurses Credentialing Center Magnet Conference in Philadelphia
Visit Covalon at booth 1557 from October 13 to October 15, 2022 at the Pennsylvania Convention Center
MISSISSAUGA, ON, Oct. 11, 2022 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its participation in the American Nurses Credentialing Center (ANCC) Magnet Conference in Philadelphia from Thursday, October 13 to Saturday, October 15, 2022. Register now and visit Covalon at booth 1557 to learn how Covalon's infection prevention and advanced wound care solutions reduce CLABSIs and help sick kids to be kids.
"We know that children who are in the hospital for treatment want to have their siblings come visit without the risk of IV line contamination. They want to be able to play on the floor, free from the worry of infection," said Brian Pedlar, CEO of Covalon. "We've designed advanced medical technology with this freedom in mind. Freedom from the risk of infection, freedom from worried parents and freedom to just be kids. We hope that more healthcare professionals will learn about the difference our compassionate care solutions make to children and their caregivers."
71% of catheter-related infections have been linked to a catheter hub contamination – VALGuard was developed to prevent these infections. From tiny babies in the NICU who pull on their lines to children walking down the hospital hallway pushing their IV pole, VALGuard is the world's only vascular access line guard that provides protection from external contaminants.
Covalon's compassionate care technology solutions for infection prevention include the following:
- VALGuard® - an FDA listed, transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal.
- IV Clear® - an antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It uses a soft silicone adhesive to preserve the skin's barrier function and minimize skin injuries and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation.
- SurgiClear® - is the world's only dual-antimicrobial clear postoperative dressing that provides full visibility, allowing for visual surgical site inspection and thus eliminating the need for early dressing removal.
- CovaClear® IV - uses the same trusted silicone adhesive technology to protect patients from skin injuries and promote healing in patients who either don't require, or cannot tolerate, antimicrobials.
Dates: October 13 –15, 2022
Location: Pennsylvania Convention Center (1101 Arch St, Philadelphia, PA 19107, United States)
Register at: https://www.magnetpathwaycon.org
For healthcare providers who are not able to attend the conference but are interested in learning more about Covalon's solutions, visit www.covalon.com or follow Covalon on LinkedIn, Facebook, Instagram or Twitter.
Covalon Technologies Ltd. is a researcher, developer, manufacturer, and marketer of patent-protected medical products that improve patient outcomes and save lives in the areas of advanced wound care, infection management and surgical procedures. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon's name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the three and nine months ended June 30, 2022, which is available on the Company's profile at www.sedar.com, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events or otherwise, except as required by law.
SOURCE Covalon Technologies Ltd.
To learn more about Covalon, please contact: Brian Pedlar, CEO, Covalon Technologies Ltd., Email: [email protected], Phone: 905.568.8400 x 233, Toll-Free: 1.877.711.6055, Website: https://covalon.com/, Twitter: @covalon
Share this article